Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 653 trials

Evaluating Safety of COR-1389

We are studying a new medication called COR-1389 to see how safe it is and how well the body tolerates it. This research may help improve treatment options in the future.

Obesity1-2 yearsSafety phase (I)EndocrinologyNephrology

RES-010 for Overweight and Moderately Obese Adults

We are investigating a new medication to see how safe it is and how it affects the body in healthy adults who are overweight or moderately obese. This study aims to gather important information about its potential benefits.

Obesity1-2 yearsSafety phase (I)EndocrinologyInternal Medicine

Gastric Cancer: IP Paclitaxel and Systemic Therapy Study

We are comparing the effects of intraperitoneal paclitaxel combined with standard therapy against standard therapy alone in patients with gastric cancer and peritoneal metastases. This study aims to see if the combination improves survival and quality of life.

Metastatic Gastric Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Gastrointestinal Stromal Tumors: IDRX-42 Treatment Study

We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.

Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Rheumatoid Arthritis: CAR-T Therapy vs. Rituximab

We are comparing a new CAR-T cell therapy with rituximab for patients with active rheumatoid arthritis that hasn't responded to other treatments. The goal is to see which therapy is safer and more effective.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesRheumatology

Thyroid Eye Disease: VRDN-003 Treatment Study

We are investigating whether VRDN-003 can improve symptoms in individuals with active thyroid eye disease. The study will also check if the treatment is safe and well-tolerated compared to a placebo.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Seizures in Developmental and Epileptic Encephalopathy: Bexicaserin (LP352)

We are studying the safety and effectiveness of a new medication, bexicaserin, for treating seizures in children and adults with developmental and epileptic encephalopathy. This research aims to understand how well it works for managing their condition.

Developmental and Epileptic Encephalopathies1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Prostate Cancer: Apalutamide with Surgery

We are studying if adding apalutamide to standard hormone therapy helps men with high-risk prostate cancer after surgery. The goal is to see if this combination improves cancer control compared to hormone therapy alone.

Metastatic Prostate Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Levosimendan Therapy for Low Ejection Fraction Takotsubo Syndrome

We are studying whether levosimendan can help improve heart function and reduce serious health risks in patients with Takotsubo syndrome. This trial compares the medication to a placebo to see if it makes a difference.

Takotsubo Syndrome1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteCardiologyInternal Medicine

Short Bowel Syndrome: HM15912 Treatment Study

We are testing HM15912 to see if it is safe and well-tolerated in adults with Short Bowel Syndrome. This study will help us understand how the treatment works in the body.

Short Bowel Syndrome1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

Eosinophilic Asthma: Benralizumab Treatment Study

We are studying how well benralizumab works and its safety for people with eosinophilic asthma who are not well-controlled on standard treatments. This trial compares it to increasing their current medication dose.

Eosinophilic Asthma1-2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Hepatocellular Carcinoma: 68Ga-PSMA PET Imaging Study

We are evaluating a new imaging method to see if it can better detect recurrence of liver cancer in patients who have been treated before. This study aims to improve monitoring and treatment strategies for these patients.

Liver Cancer1-2 yearsSafety phase (I)Efficacy phase (II)HepatologyOncology

Cemiplimab for High-Risk Skin Cancer

We are studying whether the immunotherapy Cemiplimab can help prevent cancer recurrence in patients with high-risk stage III/IV skin cancer who can undergo surgery.

Cutaneous Squamous Cell CarcinomaSurgically Resectable, High Risk Stage III/IV Cutaneous Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatologyOncology

Desmoid Tumors: Nirogacestat Study for Women

We are studying how Nirogacestat affects ovarian function in adult premenopausal women with desmoid tumors. The trial aims to understand any ovarian toxicity and the overall safety of the treatment.

Desmoid Tumors (Aggressive Fibromatosis)1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Ulcerative Colitis: SAR442970 Study

We are investigating how effective different doses of SAR442970 are for adults with moderate to severe ulcerative colitis. The study aims to see if it can help improve symptoms and overall quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterology

Melanoma, Breast Cancer, and Head & Neck Cancer: Contrast-Enhanced Ultrasound Study

We are exploring whether contrast-enhanced ultrasound can better locate sentinel nodes during surgery compared to the current standard method. This study aims to improve detection and potentially predict if the nodes are cancerous.

Breast CancerMelanomaHead and Neck Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncologyOtolaryngology

ALN-F1202: Safety Study in Healthy Adults

We are testing a new treatment called ALN-F1202 to see if it is safe and well-tolerated in healthy adults. This study is important for future research on its use in patients.

Hereditary Angioedema1-2 yearsSafety phase (I)Allergology

Steroid Treatment for Wheezing in Children

We are studying whether a new steroid treatment can help prevent asthma in children who wheezed for the first time after a rhinovirus infection. The trial will also look at the frequency and severity of wheezing episodes over time.

Acute Wheezing/Bronchiolitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases

DENOCHARCOT Trial: DENOsumab for Charcot Foot in Diabetes

We are studying whether DENOsumab can effectively treat acute Charcot foot in people with diabetes. This trial compares the medication to a placebo to assess its impact on health outcomes.

Diabetic Charcot Foot1-2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology